Abstract:Objective To study the treatment outcomes of multidrug-resistant pulmonary tuberculosis and analyze the factors associated with treatment outcome in Wenzhou.Methods Data of 198 MDR-TB patients diagnosed from August 2013 to December 2015 were retrospectively collected.Among them,10 patients refused to accept treatment,3 patients died and 2 patients were lost to follow-up before treatment,the chemotherapy regimens and treatment outcomes of 43 patients were unknown,the baseline strain of 1 patient was confirmed as sensitive by the drug sensitivity test three times,the baseline strains of 7 patients were identified as non-tuberculous mycobacteria by 16S rRNA and hsp65 gene,and 16 patients received non-standardized multidrug-resistant tuberculosis regimens.Finally 116 patients received standardized regimens for MDR-TB.We recorded their baseline clinical characteristics,baseline drug susceptibility results,sputum culture conversion,clinical symptom and imaging changes.The primary endpoint was cure,treatment completed,treatment failure,death,or default (lost to follow-up) at the end of the treatment period.Results Of 116 patients enrolled into the standardized regimens for MDR-TB,the number of new patients and previously treated patients were 39 (33.6％) and 77 (66.4％),respectively.There were 83 male patients accounting for 71.6％ and 33 female patients accounting for 28.4％.The average age was (48.7 ± 12.6) years old and the age ranged from 15 to 77 years old.Of the 116 MDR-TB patients,59 (50.9％) were cured or completed treatment,19 (16.4％) experienced treatment failure,5 (4.3％) died,and 33 (28.4％) were lost to follow-up.The success rate of new patients was higher than that of previously treated patients (69.2％ vs 41.6％),and the difference was statistically significant (x2 =7.932,P =0.005).The success rate of MDR-TB (67.7 ％,21/31) was higher than that of pre-XDR-TB (42.6％,20/47) and XDR-TB (15.4％,2/13),the differences were statistically significant (x2 =4.753,P =0.029 and x2 =10.064,P =0.002).The loss rate of MDR-TB (25.8 ％,8/31) was respectively compared with that of pre-XDR-TB (27.7％,13/47) and XDRTB (23.1％,3/13),while there was no statistically significant difference among them (x2 =0.033,P=0.857;x2 =0.036,P=0.849).Of the 91 patients with baseline second-line drug susceptibility,34.1％ (31/91),51.6％ (47/91) and 14.3％ (13/91),respectively,was simple MDR-TB,pre-XDR-TB,and XDR-TB.And the resistant proportion of ofloxacin accounted for 63.7％ (58/91).Simple MDR-TB (87.1％,27/31) was higher than the pre-XDR-TB (66.0％,31/47) and XDR-TB (38.5％,5/13) in terms of sputum culture conversion rates,the difference were statistically significant (log-rank trend test,x2=14.500,P＜0.001).Conclusion The low success rates of MDR-TB treatment in Wenzhou may be related to the high proportion of Pre-XDR-TB and XDR-TB and the high default rates.

Acquired Drug Resistance During the Turnaround Time for Drug Susceptibility Testing Impacts Outcome of Tuberculosis

Acquired Drug Resistance During the Turnaround Time for Drug Susceptibility Testing Impacts Outcome of Tuberculosis.

Additional Drug Resistance for Mycobacterium Tuberculosis During Turnaround Time for Drug-Susceptibility Testing in China: A Multicenter Observational Cohort Study

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai

Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment

Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China

The past, present and future of tuberculosis treatment.

Drug Exposure and Susceptibility of Second-Line Drugs Correlate with Treatment Response in Patients with Multidrug-Resistant Tuberculosis: a Multicentre Prospective Cohort Study in China.

Experiences in Anti-Tuberculosis Treatment in Patients with Multiple Previous Treatments and Its Impact on Drug Resistant Tuberculosis Epidemics.

Improved Treatment Outcome of Multidrug-Resistant Tuberculosis with the Use of a Rapid Molecular Test to Detect Drug Resistance in China.

Risk Factors For Poor Treatment Outcomes In Patients With Mdr-Tb And Xdr-Tb In China: Retrospective Multi-Center Investigation

Factors associated with treatment outcomes of patients with drug-resistant tuberculosis in China: A retrospective study using competing risk model

Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition

Transmission of Drug-Resistant Tuberculosis among Treated Patients in Shanghai, China

Treatment outcomes of the standardized regimens for patients with multidrug-resistant pulmonary tuberculosis in Wenzhou during 2013 to 2015

Pnca Mutations Are Associated with Slower Sputum Conversion During Standard Treatment of Multidrug-Resistant Tuberculosis.

Clinical Characteristics and Outcome Predictors in Drug-Resistant Tuberculosis: A Comprehensive Analysis

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China

Risk factors for drug-resistant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China, during 2004–2019